+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 99Years
All Genders
ID06681051

Evaluating OSTENIL4 TENDON Effectiveness and Safety for Pain and Movement Issues in Tendinopathy

Led by TRB Chemedica AG · Updated on 2026-11-03

84

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of OSTENIL4 TENDON, a device used to treat pain and limited movement caused by four specific tendon disorders patella tendon, peroneal tendon, medial epicondylus humeri, and iliotibial band tendinopathy. This observational study aims to gather real-life data on the treatments impact when used according to the official instructions. Participants receive two injections of a 2% sodium hyaluronate solution OSTENIL4 TENDON spaced one week apart. The treatment focuses on improving symptoms in the affected tendons, with assessments extending up to 24 weeks after treatment to monitor changes and safety. The study observes participants without randomization or placebo comparison. During the study, participants undergo regular evaluations including pain intensity measurement using a visual analogue scale, functional ability scales for upper or lower extremities, and both patient- and investigator-reported outcome measures. Assessments occur at baseline and at multiple points up to 24 weeks post-treatment. Safety is closely monitored for adverse events related to the device or procedure throughout the follow-up period. The total participation length covers baseline through 24 weeks after treatment completion.

CONDITIONS

Brief Title

Effectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders

Research Team

R

Raphaela Geiger

V

Veronika Mussack, Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here